| The analysis of GSTA1 promoter genetic and functional diversity of human populations | Scientific reports |  | | 2021 | 287 | 407 |
|
| Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation | Biology of Blood and Marrow Transplantation |  | | 2020 | 348 | 0 |
|
| Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation | British Journal of Clinical Pharmacology | | | 2018 | 380 | 244 |
|
| Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation | The Pharmacogenomics Journal | | | 2018 | 529 | 292 |
|
| Development and validation of an allele-specific PCR assay for genotyping a promoter and exonic single nucleotide polymorphisms of MGMT gene | Journal of Biological Methods | | | 2018 | 324 | 169 |
|
| GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation | Biology of Blood and Marrow Transplantation | | | 2017 | 503 | 17 |
|
| GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study | Oncotarget | | | 2017 | 562 | 341 |
|
| Potential Predictive Biomarkers used to optimize treatments for Sinusoidal Obstruction Syndrome in pediatric Hematopoietic stem cell transplantation | Bulletin suisse du cancer | | | 2016 | 455 | 1,799 |
|
| Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use | International Journal of Molecular Sciences | | | 2016 | 589 | 635 |
|
| Creation of the Swiss group of pharmacogenomics and personalized therapy (SPT) | Paediatrica | | | 2016 | 394 | 139 |
|
